Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Danaher Corp. pages available for free this week:
- Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to FCFF (EV/FCFF)
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Dividend Discount Model (DDM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Price to Earnings (P/E) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Danaher Corp. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).
- Debt to Equity
- The debt to equity ratio exhibits a consistent downward trend from April 2020 through the mid-2024 periods, decreasing from 0.84 to around 0.34. This indicates a progressive reduction in reliance on debt financing relative to equity, suggesting an improvement in the company's financial structure. Minor fluctuations are observed, such as a slight increase to 0.42 in September 2023, but the overall direction remains downward through the latest periods, ending around 0.32-0.33.
- Debt to Capital
- This ratio shows a similar decreasing trend over the analyzed timeline, moving from 0.46 in April 2020 to approximately 0.24-0.25 by mid-2025. The steady reduction points to a lower proportion of debt within the company's overall capital, reinforcing an improvement in capital structure and reduced financial risk. Small upticks appear intermittently, for example around September 2023 and June 2025, but the predominant trend is downward.
- Debt to Assets
- The debt to assets ratio decreases from 0.38 in early 2020 to about 0.21 by mid-2025. This decline reflects a shrinking dependency on debt in relation to total assets, indicating enhanced asset backing by equity and potentially a stronger balance sheet position. The ratio remains relatively stable after 2022 with minor fluctuations between 0.21 and 0.25, maintaining a generally low and stable level.
- Financial Leverage
- Financial leverage decreases steadily from 2.22 in April 2020 to approximately 1.56 by the latter part of 2025. This reduction suggests a gradual decrease in the firm’s use of debt relative to equity, implying a more conservative leverage approach over time. The downward trend signifies enhanced financial stability and potentially lower financial risk exposure, with values stabilizing around 1.56 in recent quarters.
- Interest Coverage
- Interest coverage data begins in October 2020 with a value of 17.35 and increases to a peak of 41.32 in December 2022. This significant improvement suggests that earnings before interest and taxes have substantially increased relative to interest expense, indicating stronger profitability and capacity to service debt. However, a gradual decline follows this peak, bringing the ratio down to approximately 15.01 by June 2025. Despite the decrease, the level remains relatively high, implying adequate coverage of interest obligations over the entire period.
Debt Ratios
Coverage Ratios
Debt to Equity
Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | Dec 31, 2020 | Oct 2, 2020 | Jul 3, 2020 | Apr 3, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Notes payable and current portion of long-term debt | |||||||||||||||||||||||||||||
Long-term debt, excluding current portion | |||||||||||||||||||||||||||||
Total debt | |||||||||||||||||||||||||||||
Total Danaher stockholders’ equity | |||||||||||||||||||||||||||||
Solvency Ratio | |||||||||||||||||||||||||||||
Debt to equity1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Debt to Equity, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).
1 Q2 2025 Calculation
Debt to equity = Total debt ÷ Total Danaher stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
- Total debt
- The total debt exhibited a generally declining trend from April 2020 to mid-2024, decreasing from $25,972 million to a low of $16,005 million in March 2025. There were intermittent increases, notably in the second half of 2021 and the last quarter of 2023, when debt rose to $23,598 million and $22,060 million respectively. However, these increases were temporary, followed by subsequent reductions. Overall, the data reflect a strategic effort to reduce leverage over the analyzed periods.
- Total stockholders' equity
- The stockholders’ equity showed consistent growth over the examined timeframe. Starting at $31,055 million in April 2020, it rose steadily to reach $52,334 million by June 2025. The equity increased at a relatively stable pace, with occasional accelerations, especially from the end of 2021 to the end of 2022, where it grew from $45,167 million to $50,082 million. This progressive expansion signals strengthening financial foundation and value creation for shareholders.
- Debt to equity ratio
- The debt to equity ratio reveals a notable declining pattern, starting at 0.84 in April 2020 and decreasing to approximately 0.32-0.34 from the end of 2023 onwards. This steady reduction suggests decreasing financial leverage and improved balance sheet risk profile. Slight fluctuations occurred, including minor ratio increases corresponding to periods when total debt rose. Nonetheless, the overall trend shows a shift towards a more conservative capital structure with lower reliance on debt financing relative to equity.
- Summary
- Over the analyzed periods, the financial data reflect a consistent strategy of debt reduction complemented by growing equity, resulting in a declining debt to equity ratio. These trends indicate stronger capitalization, reduced financial risk, and enhanced potential for sustainable growth. Occasional increases in debt appear to be managed effectively within the context of robust equity growth, maintaining a stable and improving financial condition.
Debt to Capital
Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | Dec 31, 2020 | Oct 2, 2020 | Jul 3, 2020 | Apr 3, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Notes payable and current portion of long-term debt | |||||||||||||||||||||||||||||
Long-term debt, excluding current portion | |||||||||||||||||||||||||||||
Total debt | |||||||||||||||||||||||||||||
Total Danaher stockholders’ equity | |||||||||||||||||||||||||||||
Total capital | |||||||||||||||||||||||||||||
Solvency Ratio | |||||||||||||||||||||||||||||
Debt to capital1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Debt to Capital, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).
1 Q2 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
- Total Debt
-
Total debt exhibited a general downward trend over the observed periods. Starting at US$25,972 million in April 2020, it decreased substantially to US$20,277 million by April 2021. There was a modest fluctuation thereafter, with a slight increase to US$23,598 million by October 2021, followed by a resumption of the declining pattern. By June 2024, total debt had reached a low of US$16,005 million before slightly rising again towards the end of the dataset, ending at US$17,355 million in June 2025. Overall, the data indicates a strategic deleveraging with intermittent borrowing activity.
- Total Capital
-
Total capital showed a steady increase from US$57,027 million in April 2020 to a peak of US$74,467 million in September 2023. After this peak, total capital underwent a gradual decline, dropping to US$65,548 million by March 2025. This pattern suggests expansion followed by a contraction or recalibration of invested capital. The capital base maintained a relatively high level throughout the periods, reflecting ongoing investment or operational scale.
- Debt to Capital Ratio
-
The debt to capital ratio demonstrated a consistent downward trajectory from 0.46 in April 2020 to 0.24 by March 2025. This decline aligns with the reduction in total debt relative to the total capital base. The ratio fell steadily with minor fluctuations, indicating improved capital structure strength and reduced financial risk over time. Notably, slight upticks in the ratio coincided with periods of increased borrowing, but these were temporary and followed by further decreases.
- Overall Insights
-
The data reveals a financial strategy focused on lowering leverage and strengthening the capital structure. Despite some variability in total debt, the consistent reduction in the debt to capital ratio points to effective debt management relative to the company’s capital. The expansion in total capital until late 2023, followed by a moderate reduction, may reflect changes in business investment or asset management strategies. The combination of decreasing debt and initially rising capital base suggests a deliberate effort to improve financial stability and flexibility.
Debt to Assets
Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | Dec 31, 2020 | Oct 2, 2020 | Jul 3, 2020 | Apr 3, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Notes payable and current portion of long-term debt | |||||||||||||||||||||||||||||
Long-term debt, excluding current portion | |||||||||||||||||||||||||||||
Total debt | |||||||||||||||||||||||||||||
Total assets | |||||||||||||||||||||||||||||
Solvency Ratio | |||||||||||||||||||||||||||||
Debt to assets1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Debt to Assets, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).
1 Q2 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
- Total Debt
- The total debt shows a generally declining trend from April 2020 to June 2024, decreasing from approximately $25.97 billion to around $17.36 billion by the end of the observed period. There are intermittent fluctuations, notably an increase around October 2021 and again in late 2023, but the overall direction is downward, indicating efforts toward debt reduction or lower borrowing requirements over time.
- Total Assets
- Total assets have exhibited a more variable pattern. Starting at about $68.93 billion in April 2020, assets increased steadily through late 2021, reaching a peak near $87.73 billion by September 2023. However, after this peak, there is a moderate decline and some fluctuations, ending the period at roughly $81.62 billion in June 2024. This suggests asset growth with some periods of asset rebalancing or disposals following the peak.
- Debt to Assets Ratio
- The debt to assets ratio has improved over the period, moving from 0.38 in April 2020 to approximately 0.21 by June 2024. This steady decrease in the ratio signals enhanced financial leverage management, reflecting a reduction in debt relative to the asset base. The ratio confirms the trends observed separately in debt and asset levels, implying enhanced balance sheet strength and potentially lower financial risk.
Financial Leverage
Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | Dec 31, 2020 | Oct 2, 2020 | Jul 3, 2020 | Apr 3, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Total assets | |||||||||||||||||||||||||||||
Total Danaher stockholders’ equity | |||||||||||||||||||||||||||||
Solvency Ratio | |||||||||||||||||||||||||||||
Financial leverage1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Financial Leverage, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).
1 Q2 2025 Calculation
Financial leverage = Total assets ÷ Total Danaher stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals a set of trends regarding the total assets, stockholders' equity, and financial leverage ratios over the examined period.
- Total Assets
- Total assets showed an overall upward trend from approximately $68,930 million in April 2020 to a peak above $87,734 million by September 2023. After this peak, a gradual decline is observed, with assets decreasing to roughly $78,542 million by March 2025, followed by a slight recovery to about $81,620 million by June 2025. The fluctuations in total assets suggest periods of asset growth that were partly reversed in later quarters.
- Total Danaher Stockholders’ Equity
- Stockholders’ equity consistently increased from around $31,055 million in April 2020 to a high near $53,486 million by December 2023. Following this peak, there is a moderate decrease towards the mid-$49,000 million range by March 2025. However, the equity figures partially recover to about $52,334 million by June 2025. This pattern indicates sustained growth in equity with some recent contractions.
- Financial Leverage
- The financial leverage ratio exhibits a clear downward trajectory from 2.22 in April 2020 to approximately 1.56 by June 2025. This steady decline implies a progressively lower reliance on debt relative to equity over the analyzed period, reflecting an improving capital structure and potentially lower financial risk.
In summary, the data indicate that both total assets and stockholders' equity have grown notably over the medium term but faced some decline in the latest periods. Meanwhile, the consistent decrease in financial leverage suggests a strategic reduction in leverage, enhancing financial stability. These trends collectively reflect an overall strengthening of the balance sheet despite recent asset and equity contractions.
Interest Coverage
Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | Dec 31, 2020 | Oct 2, 2020 | Jul 3, 2020 | Apr 3, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Net earnings | |||||||||||||||||||||||||||||
Less: Earnings from discontinued operations, net of income taxes | |||||||||||||||||||||||||||||
Add: Income tax expense | |||||||||||||||||||||||||||||
Add: Interest expense | |||||||||||||||||||||||||||||
Earnings before interest and tax (EBIT) | |||||||||||||||||||||||||||||
Solvency Ratio | |||||||||||||||||||||||||||||
Interest coverage1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Interest Coverage, Competitors2 | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).
1 Q2 2025 Calculation
Interest coverage
= (EBITQ2 2025
+ EBITQ1 2025
+ EBITQ4 2024
+ EBITQ3 2024)
÷ (Interest expenseQ2 2025
+ Interest expenseQ1 2025
+ Interest expenseQ4 2024
+ Interest expenseQ3 2024)
= ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data reveals several noteworthy trends in the company's operating performance and interest obligations over the observed periods.
- Earnings Before Interest and Tax (EBIT)
- The EBIT values demonstrate significant variability across the periods. Starting at 759 million USD in early 2020, EBIT increased substantially to reach peaks exceeding 2,100 million USD in multiple quarters between 2021 and 2022. Following the peak in December 2022 (2,257 million USD), EBIT shows a declining trend, dropping to 726 million USD by mid-2025. This decline reflects a reduction in operational profitability or income generation capability towards the latter periods.
- Interest Expense
- Interest expenses remain relatively stable but with slight fluctuations, varying between 42 million USD and 87 million USD across the timeline. There is no clear upward or downward trend, although some quarters experience moderate increases, suggesting stable but fluctuating borrowing costs or debt levels.
- Interest Coverage Ratio
- The interest coverage ratio is consistently high throughout the periods, indicating strong ability to meet interest obligations from operating earnings. It rises from a value around 17 in early 2020 to a peak above 40 in late 2021 and early 2022, before gradually tapering down to approximately 15 by mid-2025. Despite this decline, the ratio remains comfortably above 1, reflecting ongoing adequate coverage of interest payments by EBIT.
Overall, the data suggests that the company experienced robust operational performance with high EBIT and strong interest coverage through 2021 and 2022. However, a downturn in EBIT starting in late 2022 leads to a commensurate decline in interest coverage ratios, even as interest expenses remain relatively stable. This could imply emerging pressures on profitability and the capacity to service debt, warranting attention in future periods.